Hospitals | April 08, 2026
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
Board approves five-year appointment, subject to shareholder nod through postal ballot
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
Subscribe To Our Newsletter & Stay Updated
